INT181267

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 14
Disease Relevance 7.60
Pain Relevance 2.70

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

vesicle-mediated transport (USE1) endoplasmic reticulum (USE1) lysosome (USE1)
Anatomy Link Frequency
shelf 1
urine 1
USE1 (Homo sapiens)
Pain Link Frequency Relevance Heat
methotrexate 65 100.00 Very High Very High Very High
aspirin 53 100.00 Very High Very High Very High
Infliximab 201 99.84 Very High Very High Very High
psoriasis 7 98.92 Very High Very High Very High
cINOD 37 98.68 Very High Very High Very High
Arthritis 28 96.36 Very High Very High Very High
Adalimumab 228 92.64 High High
Spinal cord 4 84.64 Quite High
ischemia 24 82.88 Quite High
headache 13 76.48 Quite High
Disease Link Frequency Relevance Heat
Disease 393 100.00 Very High Very High Very High
Nicotine Addiction 90 99.56 Very High Very High Very High
Cramps 1 99.16 Very High Very High Very High
Toxicity 11 99.04 Very High Very High Very High
Psoriasis 8 98.92 Very High Very High Very High
INFLAMMATION 77 98.20 Very High Very High Very High
Autoimmune Disease 4 97.88 Very High Very High Very High
Demyelinating Disease 9 97.00 Very High Very High Very High
Seronegative Spondarthritis 21 96.36 Very High Very High Very High
Systemic Lupus Erythematosus 11 94.68 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Currently, surgeons performing ACL reconstruction use screws, pins, buttons, and cramps for graft fixation because of individual preference, or institutional orders.
Gene_expression (screws) of use associated with cramps
1) Confidence 0.32 Published 2005 Journal BMC Surg Section Body Doc Link PMC552311 Disease Relevance 0.19 Pain Relevance 0
Although the study sample size was small, the outcome of this phase II trial concluded that trabectedin induced responses in 17% of study patients with a one year overall survival rate of 72%.32 These results rivaled those from other first-line studies using doxorubicin and ifosfamide.33–35

Compassionate use trials

Gene_expression (trials) of use
2) Confidence 0.16 Published 2010 Journal Core evidence Section Body Doc Link PMC2899778 Disease Relevance 0.85 Pain Relevance 0
In this experimental analogue study, smokers who were asked to imagine that they had a gene variant that predicted a good response to bupropion, a medicine used to facilitate smoking cessation, were more likely to select the use of bupropion, the more effective treatment given their gene variant, to assist them in quitting.
Gene_expression (select) of use associated with nicotine addiction
3) Confidence 0.08 Published 2010 Journal BMC Public Health Section Body Doc Link PMC2996370 Disease Relevance 0.70 Pain Relevance 0.03
Patients (n=313) were stratified according to MTX use (yes or no) and extent of psoriasis involvement (?
Gene_expression (stratified) of use associated with psoriasis and methotrexate
4) Confidence 0.08 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936294 Disease Relevance 1.24 Pain Relevance 1.18
Considering its growing use for hematological reconstitution, its widespread availability and the potential use in non-hematopoietic related-diseases, CB is an attractive source for tissue regeneration [12,13].
Gene_expression (source) of use associated with disease
5) Confidence 0.08 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2956109 Disease Relevance 0.57 Pain Relevance 0.14
Considering its growing use for hematological reconstitution, its widespread availability and the potential use in non-hematopoietic related-diseases, CB is an attractive source for tissue regeneration [12,13].
Gene_expression (source) of use associated with disease
6) Confidence 0.08 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2956109 Disease Relevance 0.64 Pain Relevance 0.17
Regarding some of these aspects, subanalyses from PRECiSE 2 have shown that CZP was effective in most patients regardless of prior use of infliximab or concomitant immunosuppressant or glucocorticoid treatment (Colombel et al. 2007c).
Gene_expression (effective) of use associated with infliximab
7) Confidence 0.04 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012434 Disease Relevance 0.22 Pain Relevance 0.29
Besides immunogenicity, several other factors limit the use of infliximab, such as toxicity, cardiovascular and autoimmune disorders, demyelinating disease, and a 1% mortality rate, reported in 500 patients after a median follow-up of 17 (range, 0–48) months (Colombel et al. 2004).
Gene_expression (limit) of use associated with toxicity, autoimmune disease, infliximab and demyelinating disease
8) Confidence 0.04 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012434 Disease Relevance 1.36 Pain Relevance 0.48
10 mg/L), baseline steroid and immunosuppressant use (Fig. 2).
Gene_expression (immunosuppressant) of use
9) Confidence 0.04 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012434 Disease Relevance 0.23 Pain Relevance 0
Mutation of the USEs in duplicate (USE 1,2 mut; USE 2,3 mut; USE 1,3 mut) resulted in approximately the same level of reduced polyadenylation efficiency as the USE 3 mut alone (Figure 4C).
Gene_expression (alone) of USE 3
10) Confidence 0.03 Published 2005 Journal Nucleic Acids Research Section Body Doc Link PMC1088970 Disease Relevance 0 Pain Relevance 0
Urine Tx-M and, to a lesser degree, urine PGI-M concentrations also were reduced significantly with ASA use in the compliant group (P<0.0001 and P<0.05).
Gene_expression (reduced) of ASA use in urine associated with aspirin
11) Confidence 0.03 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2824826 Disease Relevance 0 Pain Relevance 0.40
The reference lists of appropriate studies and review articles were reviewed for additional sources regarding the use of PRP and rhPDGF-BB.


Gene_expression (sources) of use
12) Confidence 0.03 Published 2010 Journal The Yale Journal of Biology and Medicine Section Body Doc Link PMC2844688 Disease Relevance 0.86 Pain Relevance 0
The short shelf life of recombinant human growth factors such as rhPDGF-BB is not a concern with the use of PRP, which can be made as needed from an autologous donation [13].
Gene_expression (made) of use in shelf
13) Confidence 0.03 Published 2010 Journal The Yale Journal of Biology and Medicine Section Body Doc Link PMC2844688 Disease Relevance 0.28 Pain Relevance 0
To minimise the data collection load for busy units, the trial will collaborate with the Paediatric Intensive Care Audit Network (PICANet http://www.picanet.org.uk) to make best use of the established data collection infrastructure which exists in all PICUs in the UK.
Gene_expression (make) of use
14) Confidence 0.01 Published 2010 Journal BMC Pediatr Section Body Doc Link PMC2830203 Disease Relevance 0.46 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox